FluoroPharma Medical Announces Acceptance of Abstract From Phase II Clinical Trial of CardioPET (18F FCPHA) for Oral ...

FluoroPharma Medical, Inc. , a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography technology for the detection and assessment of disease ...



from Google News, Yahoo! News, Wikinews, NY Times National News by search term http://ift.tt/1ntEjlo

via IFTTT